Trials / Completed
CompletedNCT06202417
Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 520 (actual)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Fruquintinib is an oral tyrosine kinase inhibitor (TKI), which improves progression-free survival (PFS) and overall survival (OS) in patients with refractory metastatic colorectal cancer (mCRC). Here, we explore the real-world treatment patterns of fruquintinib in the third- or late-line setting for mCRC in six centers in China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fruquintinib | an oral tyrosine kinase inhibitor (TKI) |
Timeline
- Start date
- 2021-01-01
- Primary completion
- 2022-06-30
- Completion
- 2023-12-25
- First posted
- 2024-01-11
- Last updated
- 2024-01-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06202417. Inclusion in this directory is not an endorsement.